RT Journal Article
SR Electronic
T1 A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-<sup>18</sup>F-Fluorothymidine and <sup>18</sup>F-FDG
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 186
OP 194
DO 10.2967/jnumed.107.044966
VO 49
IS 2
A1 Tian, Jiahe
A1 Yang, Xiaofeng
A1 Yu, Lijuan
A1 Chen, Ping
A1 Xin, Jun
A1 Ma, Liming
A1 Feng, Huiru
A1 Tan, Yieyin
A1 Zhao, Zhoushe
A1 Wu, Wenkai
YR 2008
UL http://jnm.snmjournals.org/content/49/2/186.abstract
AB Some new radiotracers might add useful information and improve diagnostic confidence of 18F-FDG imaging in tumors. A multicenter clinical trial was designed to investigate the diagnostic performance of dual-tracer (18F-FDG and 3′-deoxy-3′-18F-fluorothymidine [18F-FLT]) PET/CT in pulmonary nodules. Methods: Fifty-five patients underwent dual-tracer imaging in 6 imaging centers using the same models of equipment and standardized protocols. The images were interpreted by a collective group of readers who were unaware of the clinical data. The diagnostic performance using either tracer alone or dual-tracers together, with or without CT, was compared. The histological diagnosis or clinical findings in a 12-mo follow-up period served as the standard of truth. Results: In 16 patients with malignant tumor, 16 with tuberculosis, and 23 with other benign lesions, the sensitivity and specificity of 18F-FDG and 18F-FLT were 87.5% and 58.97% and 68.75% and 76.92%, respectively. The combination of dual-tracer PET/CT improved the sensitivity and specificity up to 100% and 89.74%. The 3 subgroups of patients could be best separated when the 18F-FLT/18F-FDG standardized uptake value ratio of 0.4–0.90 was used as the threshold. Conclusion: By reflecting different biologic features, the dual-tracer PET/CT using 18F-FDG and 18F-FLT favorably affected the diagnosis of lung nodules.